<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29302687</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>09</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2374-2445</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>4</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>Mar</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>JAMA oncology</Title>
          <ISOAbbreviation>JAMA Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Breast Implants and the Risk of Anaplastic Large-Cell Lymphoma in the Breast.</ArticleTitle>
        <Pagination>
          <StartPage>335</StartPage>
          <EndPage>341</EndPage>
          <MedlinePgn>335-341</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaoncol.2017.4510</ELocationID>
        <Abstract>
          <AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Breast implants are among the most commonly used medical devices. Since 2008, the number of women with breast implants diagnosed with anaplastic large-cell lymphoma in the breast (breast-ALCL) has increased, and several reports have suggested an association between breast implants and risk of breast-ALCL. However, relative and absolute risks of breast-ALCL in women with implants are still unknown, precluding evidence-based counseling about implants.</AbstractText>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine relative and absolute risks of breast-ALCL in women with breast implants.</AbstractText>
          <AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Through the population-based nationwide Dutch pathology registry we identified all patients diagnosed with primary non-Hodgkin lymphoma in the breast between 1990 and 2016 and retrieved clinical data, including breast implant status, from the treating physicians. We estimated the odds ratio (OR) of ALCL associated with breast implants in a case-control design, comparing implant prevalence between women with breast-ALCL and women with other types of breast lymphoma. Cumulative risk of breast-ALCL was derived from the age-specific prevalence of breast implants in Dutch women, estimated from an examination of 3000 chest x-rays and time trends from implant sales.</AbstractText>
          <AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Relative and absolute risks of breast-ALCL in women with breast implants.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 43 patients with breast-ALCL (median age, 59 years), 32 had ipsilateral breast implants, compared with 1 among 146 women with other primary breast lymphomas (OR, 421.8; 95% CI, 52.6-3385.2). Implants among breast-ALCL cases were more often macrotextured (23 macrotextured of 28 total implants of known type, 82%) than expected (49 193 sold macrotextured implants of total sold 109 449 between 2010 and 2015, 45%) based on sales data (P &lt; .001). The estimated prevalence of breast implants in women aged 20 to 70 years was 3.3%. Cumulative risks of breast-ALCL in women with implants were 29 per million at 50 years and 82 per million at 70 years. The number of women with implants needed to cause 1 breast-ALCL case before age 75 years was 6920.</AbstractText>
          <AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Breast implants are associated with increased risk of breast-ALCL, but the absolute risk remains small. Our results emphasize the need for increased awareness among the public, medical professionals, and regulatory bodies, promotion of alternative cosmetic procedures, and alertness to signs and symptoms of breast-ALCL in women with implants.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>de Boer</LastName>
            <ForeName>Mintsje</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Plastic, Reconstructive and Hand-Surgery, Maastricht University Medical Centre, School for Oncology and Developmental Biology, Maastricht, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>van Leeuwen</LastName>
            <ForeName>Flora E</ForeName>
            <Initials>FE</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Epidemiology and Biostatistics, Netherlands Cancer Institute, Amsterdam, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hauptmann</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Epidemiology and Biostatistics, Netherlands Cancer Institute, Amsterdam, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Overbeek</LastName>
            <ForeName>Lucy I H</ForeName>
            <Initials>LIH</Initials>
            <AffiliationInfo>
              <Affiliation>Dutch Nationwide Network and Registry of Histo- and Cytopathology, Houten, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>de Boer</LastName>
            <ForeName>Jan Paul</ForeName>
            <Initials>JP</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hijmering</LastName>
            <ForeName>Nathalie J</ForeName>
            <Initials>NJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, VU University Medical Centre, Amsterdam, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sernee</LastName>
            <ForeName>Arthur</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, VU University Medical Centre, Amsterdam, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Klazen</LastName>
            <ForeName>Caroline A H</ForeName>
            <Initials>CAH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, Medisch Spectrum Twente, Enschede, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lobbes</LastName>
            <ForeName>Marc B I</ForeName>
            <Initials>MBI</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiology and Nuclear Medicine, Maastricht University, Maastricht University Medical Centre, Maastricht, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>van der Hulst</LastName>
            <ForeName>René R W J</ForeName>
            <Initials>RRWJ</Initials>
            <AffiliationInfo>
              <Affiliation>Plastic, Reconstructive and Hand-Surgery, Maastricht, University Medical Centre, School of Nutrition and Translational, Research in Metabolism, Maastricht, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rakhorst</LastName>
            <ForeName>Hinne A</ForeName>
            <Initials>HA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Plastic, Reconstructive and Hand Surgery, Ziekenhuis Groep Twente/Medisch Spectrum Twente, Enschede, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>de Jong</LastName>
            <ForeName>Daphne</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, VU University Medical Centre, Amsterdam, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>JAMA Oncol</MedlineTA>
        <NlmUniqueID>101652861</NlmUniqueID>
        <ISSNLinking>2374-2437</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>JAMA Oncol. 2018 Mar 1;4(3):341-342</RefSource>
          <PMID Version="1">29302678</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>JAMA Oncol. 2018 Oct 1;4(10):1434-1435</RefSource>
          <PMID Version="1">30054604</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>JAMA Oncol. 2018 Oct 1;4(10):1434</RefSource>
          <PMID Version="1">30054610</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>JAMA Oncol. 2018 Oct 1;4(10):1435</RefSource>
          <PMID Version="1">30054614</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019928" MajorTopicYN="N">Breast Implantation</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018427" MajorTopicYN="N">Breast Implants</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
          <QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004198" MajorTopicYN="N">Disease Susceptibility</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017728" MajorTopicYN="N">Lymphoma, Large-Cell, Anaplastic</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009426" MajorTopicYN="N" Type="Geographic">Netherlands</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement><b>Conflict of Interest Disclosures:</b> None reported.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>1</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>9</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>1</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29302687</ArticleId>
        <ArticleId IdType="pmc">PMC5885827</ArticleId>
        <ArticleId IdType="doi">10.1001/jamaoncol.2017.4510</ArticleId>
        <ArticleId IdType="pii">2667737</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Angell M.
Shattuck Lecture—evaluating the health risks of breast implants: the interplay of medical science, the law, and public opinion. N Engl J Med. 1996;334(23):1513-1518.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8618607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Balk EM, Earley A, Avendano EA, Raman G. 
Long-term health outcomes in women with silicone gel breast implants: a systematic review. Ann Intern Med. 2016;164(3):164-175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26550776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janowsky EC, Kupper LL, Hulka BS. 
Meta-analyses of the relation between silicone breast implants and the risk of connective-tissue diseases. N Engl J Med. 2000;342(11):781-790.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10717013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Jong D, Vasmel WL, de Boer JP, et al. . 
Anaplastic large-cell lymphoma in women with breast implants. JAMA. 2008;300(17):2030-2035.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18984890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brody GS, Deapen D, Taylor CR, et al. . 
Anaplastic large cell lymphoma occurring in women with breast implants: analysis of 173 cases. Plast Reconstr Surg. 2015;135(3):695-705.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25490535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Medical Device Reports of Breast Implant-Associated Anaplastic Large Cell Lymphoma. Silver Spring, Maryland, U.S. Food &amp; Drug Administration (FDA), 2017. 
https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/BreastImplants/ucm481899.htm. Accessed March 23, 2017.</Citation>
        </Reference>
        <Reference>
          <Citation>Swerdlow SH, Campo E, Pileri SA, et al. . 
The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-2390.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4874220</ArticleId>
            <ArticleId IdType="pubmed">26980727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doren EL, Miranda RN, Selber JC, et al. . 
U.S. epidemiology of breast implant-associated anaplastic large cell lymphoma. Plast Reconstr Surg. 2017;139(5):1042-1050.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28157769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loch-Wilkinson A, Beath KJ, Knight RJW, et al. . 
Breast implant associated anaplastic large cell lymphoma in Australia and New Zealand—high surface area textured implants are associated with increased risk. Plast Reconstr Surg. 2017;140(4):645-654.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28481803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Casparie M, Tiebosch AT, Burger G, et al. . 
Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol. 2007;29(1):19-24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4618410</ArticleId>
            <ArticleId IdType="pubmed">17429138</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miranda RN, Aladily TN, Prince HM, et al. . 
Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol. 2014;32(2):114-120.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4062709</ArticleId>
            <ArticleId IdType="pubmed">24323027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paap E, Witjes M, van Landsveld-Verhoeven C, Pijnappel RM, Maas AH, Broeders MJ. 
Mammography in females with an implanted medical device: impact on image quality, pain and anxiety. Br J Radiol. 2016;89(1066):20160142.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5124797</ArticleId>
            <ArticleId IdType="pubmed">27452263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fracheboud J, de Koning HJ, Boer R, et al. ; National Evaluation Team for Breast cancer screening in The Netherlands . 
Nationwide breast cancer screening programme fully implemented in The Netherlands. Breast. 2001;10(1):6-11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14965550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim HJ, Fay MP, Feuer EJ, Midthune DN. 
Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19(3):335-351.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10649300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Population in the Netherlands; by sex and age and marital status, 1 January, 1950-2016. Heerlen, the Netherlands: Statistics Netherlands, 2017. http://statline.cbs.nl/Statweb/. Accessed February 13, 2017.</Citation>
        </Reference>
        <Reference>
          <Citation>Schouten LJ, Straatman H, Kiemeney LA, Verbeek AL. 
Cancer incidence: life table risk versus cumulative risk. J Epidemiol Community Health. 1994;48(6):596-600.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1060039</ArticleId>
            <ArticleId IdType="pubmed">7830016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>SAS Institute Inc 
2011. Base SAS 9.3 Procedures Guide. Cary, NC.</Citation>
        </Reference>
        <Reference>
          <Citation>De Boer M, van der Sluis WB, de Boer JP, et al. . 
BIA-ALCL in a transgender woman. Aesthet Surg J. 2017;37(8):NP83-NP87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29036941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blombery P, Thompson ER, Jones K, et al. . 
Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma anaplastic large cell lymphoma. Haematologica. 2016;101(9):e387-e390.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5060038</ArticleId>
            <ArticleId IdType="pubmed">27198716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kadin ME, Deva A, Xu H, et al. . 
Biomarkers provide clues to early events in the pathogenesis of breast implant-associated anaplastic large cell lymphoma. Aesthet Surg J. 2016;36(7):773-781.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26979456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu H, Johani K, Almatroudi A, et al. . 
Bacterial biofilm infection detected in breast implant associated anaplastic large cell lymphoma. Plast Reconstr Surg. 2016;137(6):1659-1669.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26890506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ye X, Shokrollahi K, Rozen WM, et al. . 
Anaplastic large cell lymphoma (ALCL) and breast implants: breaking down the evidence. Mutat Res Rev Mutat Res. 2014;762:123-132.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25475421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thomas A, Link BK, Altekruse S, Romitti PA, Schroeder MC. 
Primary breast lymphoma in the United States: 1975-2013. J Natl Cancer Inst. 2017;109(6).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6059147</ArticleId>
            <ArticleId IdType="pubmed">28376147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deva AK.
Discussion: U.S. Epidemiology of Breast Implant-Associated Anaplastic Large-Cell Lymphoma. Plast Reconstr Surg. 2017;139(5):1051-1052.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28445348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khouri RK, Rigotti G, Khouri RK Jr, et al. . 
Tissue-engineered breast reconstruction with Brava-assisted fat grafting: a 7-year, 488-patient, multicenter experience. Plast Reconstr Surg. 2015;135(3):643-658.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25719686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tuinder S, Baetens T, De Haan MW, et al. . 
Septocutaneous tensor fasciae latae perforator flap for breast reconstruction: radiological considerations and clinical cases. J Plast Reconstr Aesthet Surg. 2014;67(9):1248-1256.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24912743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faris O, Shuren J. 
An FDA Viewpoint on Unique Considerations for Medical-Device Clinical Trials. N Engl J Med. 2017;376(14):1350-1357.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28379790</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
